Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a Healthcare company (Biotechnology) with a market capitalization of $7.2B. The Maz Rating grades it against the other companies in its sector.
Axsome Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $137.01, Axsome Therapeutics, Inc. trades at 8.3x sales and 68.2x book value. Over the last twelve months it generated about $865M of revenue and a net loss of $161M. It runs a gross margin of 93.2%, an operating margin of -17.7% and a net margin of -18.2%. It shows return on equity of -189.7%, return on invested capital of -39.6% and a free cash flow yield of -1.1%. On the balance sheet: a debt-to-equity ratio of 2.07 and a current ratio of 1.42. Over the past 52 weeks the share price ranged from $123.00 to $260.19, with a beta of 0.60.
Axsome Therapeutics, Inc. does not currently pay a dividend.
27 Wall Street analyst ratings cover the stock: 26 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.